Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Table 1

Changes of variables in NGT, IGT, and DM groups from pretreatment to after SSA treatment.

The entire cohort ()

NGT ()

IGT ()

DM ()

Pre-SSA

Post-SSA

value

Pre-SSA

Post-SSA

value

Pre-SSA

Post-SSA

value

Pre-SSA

Post-SSA

value

HbA1c (%)

5.80 (5.60~6.40)

6.00 (5.50~6.50)

0.256

5.64 ± 0.27

5.78 ± 0.38

0.083

5.72 ± 0.37

5.73 ± 0.45

0.914

8.35 ± 2.47

6.88 ± 1.00

0.015^∧

FPG (mmol/l)

5.50 (5.10~6.20)

5.90 (5.40~6.38)

0.015^∧

5.08 ± 0.41

5.63 ± 0.55

<0.001^∧

5.52 ± 0.55

5.88 ± 0.68

0.025^∧

7.29 ± 2.22

6.71 ± 1.89

0.251

BG120 (mmol/l)

8.90 (7.23~12.88

8.70 (7.40~12.08)

0.477

6.23 ± 0.99

8.37 ± 1.50

<0.001^∧

8.97 ± 0.86

8.28 ± 2.48

0.233

16.00 ± 3.24

13.80 ± 4.30

0.002^∧

FPI (mU/l)

14.80 (11.00~25.18)

10.05 (6.30~20.08)

<0.001^∧

14.10 (9.70~24.10)

8.40 (4.40~18.20)

0.001^∧

19.20 (13.37~28.38)

16.45 (7.03~19.55)

0.001^∧

12.40 (5.45~20.60)

10.00 (5.00~21.30)

0.205

INS120 (mU/l)

93.85 (44.60~191.10)

63.20 (34.03~129.33)

0.001^∧

66.90 (44.70~148.90)

74.90 (56.80~131.20)

0.777

185.75 (115.50~298.31)

63.30 (41.05~192.70)

0.004^∧

44.40 (21.50~106.00)

36.20 (19.25~68.00)

0.071

HOMA-IR

4.27 (2.78~6.64)

2.39 (1.57~4.78)

<0.001^∧

3.32 (2.20~6.01)

1.94 (0.95~4.45)

0.014^∧

4.78 (3.28~7.04)

2.74 (2.07~4.73)

0.007^∧

4.08 (2.02~7.13)

2.44 (1.72~7.37)

0.073

ISOGTT

41.74 (25.72~67.28)

69.70 (42.23~117.02)

<0.001^∧

50.21 (28.35~70.91)

87.07 (46.72~145.93)

0.002^∧

31.90 (23.05~41.74)

54.34 (34.19~111.57)

<0.001^∧

49.74 (27.07~86.96)

81.46 (42.15~124.76)

0.044^∧

HOMA-β (%)

165.69 (83.85~255.24)

90.57 (52.98~169.30)

<0.001^∧

202.61 (137.50~283.53)

91.58 (60.00~154.07

<0.001^∧

188.50 (140.87~290.86)

96.77 (66.34~192.76

<0.001^∧

73.75 (27.79~137.22)

77.50 (36.84~177.09)

0.394

INS0/BG0

2.75 (1.83~4.63)

1.73 (1.05~3.28)

<0.001^∧

2.74 (1.90~4.63)

1.61 (1.00~3.31)

<0.001^∧

3.50 (2.61~5.02)

1.80 (1.26~3.69)

<0.001^∧

1.93 (0.70~3.05)

1.72 (0.74~3.20)

0.305

IGI

20.66 (6.16~45.11)

4.45 (1.89~10.21)

<0.001^∧

34.20 (16.97~60.00)

4.74 (2.80~17.50)

0.002^∧

32.69 (18.68~47.53)

9.20 (4.64~17.52)

<0.001^∧

2.15 (1.17~7.55)

1.83 (0.97~3.14)

0.117

IGI/IR

4.81 (1.67~9.16)

2.19 (0.91~4.42

<0.001^∧

9.48 (5.11~16.07)

4.09 (1.30~7.34)

0.007^∧

5.19 (3.46~7.65)

3.42 (2.26~5.01)

0.026^∧

0.71 (0.35~1.85)

0.99 (0.30~1.62)

0.360

ISSI2

457.88 (259.97~586.72)

378.35 (248.50~509.10)

0.242

587.42 (511.92~710.87)

484.22 (341.33~734.40

0.018^∧

463.70 (391.08~570.35)

454.07 (325.93~575.84)

0.808

164.30 (103.70~253.35)

204.38 (135.11~261.23)

0.355

AUCINS/AUCBG

10.74 (5.51~18.15)

5.23 (3.11~10.49)

<0.001^∧

11.51 (8.02~18.72)

5.85 (4.63~11.12)

0.001^∧

16.30 (10.74~23.22)

9.08 (4.40~12.57)

<0.001^∧

2.57 (1.23~6.34)

2.25 (1.56~4.61)

0.205

NGT: normal glucose tolerance; IGT: impaired glucose tolerance; DM: diabetes mellitus; IGF-1 index: the ratio of the measured IGF-1 value to the upper limit of normal (ULN); FPG: fasting plasma glucose; BG₁₂₀: plasma glucose 120 min during OGTT; AUC_BG: the areas under the curve of glucose; FPI: fasting plasma insulin; INS₁₂₀: plasma insulin 120 min during OGTT; AUC_INS: the areas under the curve of insulin; HOMA-IR: indicator of insulin resistance; IS_OGTT: the OGTT insulin sensitivity index; HOMA-β: homeostatic model assessment of pancreatic beta-cell function; IGI: insulinogenic index; ISSI2: the OGTT insulin secretion sensitivity index. values are for variations before and after SSA treatment; .